Corporate
2016.11.14
Lumosa presents LT3001 at the stroke forum
Taiwan Stroke Society held its 2016 Annual Meeting and the inaugural “Asia Pacific Stroke Forum" (hereafter referred to as “the Forum”) on November 12 and 13 in The Grand Hotel, Taipei. Stroke specialists and key opinion leaders all over the world were invited to discuss the newest stroke treatment methods. Dr. Sheng-Wen Yeh of Lumosa Therapeutics (Lumosa, TPEx:6535) was invited to give an orally presentation on the findings in a recent non-primate study of LT3001, a novel chemical entity under development by Lumosa for the treatment of acute ischemic stroke.
Corporate
2016.11.03
Lumosa Presents LT3001 at the thrombolysis thrombectomy and acute stroke therapy symposium
Dr. Mimi Yeh of Lumosa Therapeutics (Lumosa) presented the recent advancement in the preclinical research of LT3001 in the oral session at the 13th International Symposium on Thrombolysis Thrombectomy and Acute Stroke Therapy (TTST), held in Kobe, Japan (October 30th and November 1, 2016). TTST is one of the few international medical conferences focusing on stroke research. Lumosa was honored to be the only drug development company invited to present and the presentation titled “Study of a novel small molecule, LT3001, in a thromboembolic stroke model in non-human primates"
Corporate
2016.08.31
LT1001 clinical results accepted by the Clinical Journal of Pain
After successful execution of the license agreement with Syntano Technology Venture for China in June, Lumosa Therapeutics Co., Ltd. (TPEx 6535), receives a notification from “the Clinical Journal of Pain” (CJP) that the manuscript on LT1001 Phase III trial results was accepted for publication. “The Clinical Journal of Pain” is an esteemed international journal ranked among top 10 of clinical journals in analgesic and anesthetic field. It publishes many medical articles addressing pain management in clinical setting and new treatment models etc. for the past 30 years. The acceptance by CJP indicated LT1001 is regarded as an innovative product in clinical pain management, which deserves the recognition by international medical experts.
Corporate
2016.06.02
LT1001 out-licensed to China
Lumosa Therapeutics Co., Ltd. announced today the signing of an exclusive license agreement with Syntano Technology Venture - a Haike company (Syntano), granting Syntano the right to develop and commercialize its LT1001 product in China, Hong Kong and Macau.commercial successes with this product by our partners. Lumosa will continue to develop high potential new drugs, maximize the value of our pipeline assets and bring our shareholders the most returns”, said Dr. Tsai Chang-Hai, Chairman of Lumosa Company Board. Please click link for more information
Corporate
2016.03.25
Lumosa appoints new BOD Chairman
Lumosa Therapeutics is delighted to announce the appointment of Dr. Chang-Hai Tsai as the new Chairman of its Board succeeding Dr. Rong-jin Lin. Dr. Tsai has been devoting his efforts in academic and research fields for over 30 years, accumulating extensive knowledge and expertise in biomedical area. He is currently one of the National Policy Advisors to the President, serves as the Chairman of the Board of China Medical University Hospital & China Medical University and is also the founding chairman of Asia University. Lumosa would like to convey its appreciation to Dr. Lin. His leadership, talent and experience have been a great asset to the company in his time as Chairman.
Corporate
2016.03.09
Dr. Wendy Huang, Lumosa CEO, speaks at Women's Day event
Lumosa Therapeutics was among the five technology based companies/woman organizations invited as an exhibitor in a Ministry of Health and Welfare-sponsored International Women’ s Day event held in NTU International Conference Center. The theme of this event was “Women in Today’s Technology”. Lumosa represent the Biotechnology community at this event. President Ma and officials from the Executive Yuan and the Ministry of Health and Welfare attended the event to show their support. Lumosa's CEO, Dr. Wendy Huang shared her thoughts with the event attendees; titled “ What Does It Take to be a Successful Bio-technology Lady?”